^
    Back
    Association details:
    Biomarker:BRAF V600E + PIK3CA mutation
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Br J Cancer
    Title:

    Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib

    Published date:
    11/18/2020
    Excerpt:
    This was a cohort study on genetic alterations in patients with BRAFV600E mutant advanced colorectal cancer treated with inhibitors of the MAPK pathway....Genetic alterations in EGFR and in PIK3CA are associated with non-response....Genetic alterations in the PI3K and upstream receptor tyrosine kinases were mostly associated with intrinsic and acquired resistance.
    DOI:
    10.1038/s41416-020-01147-2